Song LD, Newhouse JP, Garcia-De-Albeniz X, Hsu J. Changes in screening colonoscopy following Medicare reimbursement and cost-sharing changes. Health Serv Res. 2019 Aug;54(4):839-50. doi: 10.1111/1475-6773.13150
Hillemeier MM, Domino ME, Wells R, Goyal RK, Kum HC, Cilenti D, Basu A. Does maternity care coordination influence perinatal health care utilization? Evidence from North Carolina. Health Serv Res. 2018 Aug;53(4):2368-83. doi: 10.1111/1475-6773.12742
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Franzini L, White C, Taychakhoonavudh S, Parikh R, Zezza M, Mikhail O. Variation in inpatient hospital prices and outpatient service quantities drive geographic differences in private spending in Texas. Health Serv Res. 2014 Dec;49(6):1944-63. doi: 10.1111/1475-6773.12192
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.